Wishing you all the joys of the season! 
Middle East & Africa Pharmacokinetics Services Market Forecast to 2031
Middle East & Africa Pharmacokinetics Services Market Forecast to 2031 – Regional Analysis – by Drug Type (Small Molecule, Large Molecule, and Vaccines), Service Type (Pre-Clinical ADME and Human Studies, PK/PD Analysis and Reporting, Dosing Simulations, Risk Analysis, and Others), Therapeutic Application (Oncology, Infectious Diseases, Neurological Disorders, Autoimmune Diseases, Gynecological Disorders, Cardiovascular Diseases, Respiratory Disorders, and Others), and End User (Pharmaceutical and Biotechnology Companies, Contract Research Organization, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Rising Prevalence of Chronic and Infectious Diseases Bolsters Middle East & Africa Pharmacokinetics Services Market
The growing prevalence of chronic diseases such as diabetes, cancer, and autoimmune diseases has been a prime enabler of drug development efforts across the world. According to the World Health Organization’s (WHO) 2024 data, ~422 million in the world suffer from diabetes, and these cases are mostly found in middle and low-income countries, causing approximately 1.5 million deaths every year. Pharmaceutical companies are at the forefront of developing drugs to treat various diseases. Pharmacokinetic studies are essential for understanding how these drugs behave in a patient’s body by analyzing the process of absorption, distribution, metabolization, and elimination (ADME) within the human body. The absorption of a drug into systemic circulation affects the speed and concentration at which a drug may reach the site of action, e.g., plasma. Drug distribution patterns throughout the body varies based on its biochemical properties and body physiology. Metabolism involves the processing of the drug by the body into subsequent compounds. This step is instrumental in converting the drug into water-soluble substances to render them suitable for renal clearance. Metabolism is also important for the conversion of prodrugs, such as codeine, into active metabolites. Excretion of drugs from the body is mainly governed by kidneys; however, in several cases, drugs may be excreted via the lungs, skin, or gastrointestinal tract. ADME dynamics define the bioavailability of drugs in the body, and the maintenance doses of drugs are calculated based on their clearance times (desired plasma concentration divided by bioavailability). Understanding of clearance allows practitioners to calculate appropriate dosing rates.
Pharmacokinetic studies focus on optimizing drug dose regimens in study subjects to understand the efficacy and safety of a drug. These studies are essential for ensuring the safety of drugs that are developed for long-term treatments, which helps evaluate the suitability and stability of drug formulations in chronic disease management. Hence, the rising burden of chronic and infectious diseases underlines the importance of pharmacokinetic studies to develop safe and effective personalized treatments.
Middle East & Africa Pharmacokinetics Services Market Overview
South Africa accounts for the largest share of the pharmacokinetics services market in the Middle East & Africa. The government of South Africa has started providing investment incentives, taking measures to protect intellectual property (IP) rights, simplifying tax rules, and levying better regulatory policies to attract foreign investments to ultimately nurture the clinical trial landscape in the country. In 2019, a total of ~US$ 62.67 million (ZAR 1 billion) was invested in upcoming and ongoing trials. During 2016-2021, ~US$ 0.18 billion (ZAR 2.95 billion) was spent by innovative multinational pharmaceutical companies operating in South Africa to support clinical research activities focused on addressing the unmet medical needs of the country.
South Africa is the most economically developed country on the African continent, and it has established better regulatory standards for clinical trials. Lower costs of clinical research operations and a minor risk of litigation make South Africa an attractive option for foreign companies outsourcing their clinical research operations. Moreover, the number of trials has been increasing due to high recruitment rates and an improved regulatory environment in the country. South Africa receives substantial sponsorships from innovative pharmaceutical companies for conducting clinical research, with no signs of slowing down. Thus, the progressing clinical research industry bolsters the growth of the pharmacokinetics services market in the country.
Middle East & Africa Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)
Middle East & Africa Pharmacokinetics Services Market Segmentation
The Middle East & Africa pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the Middle East & Africa pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the Middle East & Africa pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the Middle East & Africa pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the Middle East & Africa pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the Middle East & Africa pharmacokinetics services market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are among the leading companies operating in the Middle East & Africa pharmacokinetics services market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to Business Market Insights’ research, the Middle East & Africa pharmacokinetics services market was valued at US$ 45.97 million in 2023 and is expected to reach US$ 74.32 million by 2031, registering a CAGR of 6.2% from 2023 to 2031. Increasing adoption of big data analytics in pharmacokinetics services and rising prevalence of chronic and infectious diseases are among the critical factors attributed to drive the Middle East & Africa pharmacokinetics services market growth.
Pharmaceutical companies adopting pharmacokinetics services opt for Big Data analytics to leverage large data sets, which subsequently aids in enhanced understanding of the drug discovery process. Big data and analytics can also help in the development of Customizable Decision Support System (CDS). This system helps integrate drug-specific information on efficacy, safety, pharmacokinetics, and pharmacodynamics. It also assists healthcare professionals in personalized medicine by tailoring specific treatments based on characteristics of individual patients. CDS analytical method allows the identification of trends, correlation, and patterns that may not be determined using traditional methods of drug discovery. It also helps facilitate predictive model development that can forecast drug behavior. Thus, the increasing adoption of Big Data analytics is emerging as a new trend in the pharmacokinetics services market.
On the contrary, limited reach of pharmacokinetics service providers in emerging countries hamper the growth of Middle East & Africa pharmacokinetics services market.
Based on drug type, the Middle East & Africa pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held 50.2% market share in 2023, amassing US$ 23.09 million. It is projected to garner US$ 39.17 million by 2031 to register 6.8% CAGR during 2023-2031.
In terms of service type, the Middle East & Africa pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held 35.6% share of Middle East & Africa pharmacokinetics services market in 2023, amassing US$ 16.37 million. It is anticipated to garner US$ 28.97 million by 2031 to expand at 7.4% CAGR during 2023-2031.
By therapeutic application, the Middle East & Africa pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held 22.5% market share in 2023, amassing US$ 10.34 million. It is projected to garner US$ 18.38 million by 2031 to register 7.5% CAGR during 2023-2031.
By end user, the Middle East & Africa pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held 43.5% market share in 2023, amassing US$ 19.98 million. It is projected to garner US$ 34.05 million by 2031 to register 6.9% CAGR during 2023-2031.
By country, the Middle East & Africa pharmacokinetics services market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that the South Africa captured 38.8% share of Middle East & Africa pharmacokinetics services market in 2023. It was assessed at US$ 17.83 million in 2023 and is likely to hit US$ 30.81 million by 2031, registering a CAGR of 7.1% during 2023-2031.
Key players operating in the Middle East & Africa pharmacokinetics services market are Charles River Laboratories International Inc; Eurofins Scientific SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA, among others.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Middle East & Africa pharmacokinetics services market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pharmacokinetics Services Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market – Middle East & Africa Analysis
5.1 Middle East & Africa Pharmacokinetics Services Market Overview
5.2 Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Middle East & Africa Pharmacokinetics Services Market Analysis – by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7. Middle East & Africa Pharmacokinetics Services Market Analysis – by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8. Middle East & Africa Pharmacokinetics Services Market Analysis – by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9. Middle East & Africa Pharmacokinetics Services Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10. Middle East & Africa Pharmacokinetics Services Market – Country Analysis
10.1 Middle East and Africa
10.1.1 Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
10.1.1.1 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 South Africa: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Rest of Middle East & Africa Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Certara Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.4 Parexel International Corp
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Thermo Fisher Scientific Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Allucent
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 PACIFIC BIOLABS
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 SGS SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
12. Appendix
12.1 About The Research Team
12.2 Glossary of Terms for Pharmacokinetic Services Market
Table 1. Middle East & Africa Pharmacokinetics Services Market Segmentation
Table 2. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Drug Type
Table 3. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Service Type
Table 4. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Therapeutic Application
Table 5. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by End User
Table 6. South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Drug Type
Table 7. South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Service Type
Table 8. South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Therapeutic Application
Table 9. South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by End User
Table 10. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Drug Type
Table 11. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Service Type
Table 12. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Therapeutic Application
Table 13. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by End User
Table 14. Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Drug Type
Table 15. Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Service Type
Table 16. Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by Therapeutic Application
Table 17. Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million) – by End User
Table 18. Glossary of Terms
Figure 1. Middle East & Africa Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Middle East & Africa Pharmacokinetics Services Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Middle East & Africa Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Middle East & Africa Pharmacokinetics Services Market Share (%) – by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Middle East & Africa Pharmacokinetics Services Market Share (%) – by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Middle East & Africa Pharmacokinetics Services Market Share (%) – by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Middle East & Africa Pharmacokinetics Services Market Share (%) – by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Middle East & Africa Pharmacokinetics Services Market by Key Countries – Revenue 2023 (US$ Million)
Figure 29. Middle East & Africa Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Saudi Arabia: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 31. South Africa: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 32. United Arab Emirates: Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
Figure 33. Rest of Middle East & Africa Pharmacokinetics Services Market – Revenue and Forecast to 2031 (US$ Million)2031 (US$ Million)
The List of Companies – Middle East & Africa Pharmacokinetics Services Market
o Allucent
o Certara Inc.
o Charles River Laboratories International Inc
o Eurofins Scientific SE
o PACIFIC BIOLABS
o Parexel International Corp
o SGS SA
o Thermo Fisher Scientific Inc.
You must be logged in to post a review.
Reviews
There are no reviews yet.